Ketamine vs Spravato

Patients researching ketamine therapy in Canada frequently encounter two distinct options: generic racemic ketamine (off-label for psychiatric use; delivered IV, IM, or sublingually at private clinics) and Spravato (intranasal esketamine; Health Canada-approved for treatment-resistant depression in May 2020). They share the same underlying molecule — ketamine — but differ in enantiomer composition, route of administration, regulatory status, evidence base, and most importantly for many Canadian patients, insurance coverage. Spravato is the form most likely to have private prior-auth coverage; off-label IV ketamine is generally out-of-pocket. The clinical evidence base for IV racemic ketamine is larger and longer (Berman 2000, Zarate 2006, Murrough 2013, Singh 2016, Phillips 2019, the ELEKT-D 2023 NEJM ketamine-vs-ECT trial). The evidence base for Spravato is more recent but designed for regulatory approval (Daly 2018, Popova 2019, Daly 2019 SUSTAIN-1, Wajs 2020 SUSTAIN-2). For many Canadian patients, the practical decision is shaped less by clinical superiority — both work — and more by access, coverage, and operational fit. This article walks the comparison honestly.

Key takeaways

• Molecule: Spravato is esketamine (S-enantiomer only); generic ketamine is racemic (50% S + 50% R). The S-enantiomer has ~4× greater NMDA receptor affinity, but clinical superiority over racemic in head-to-head comparison is not established.
• Regulatory: Spravato is Health Canada-approved (May 2020) for TRD with concurrent oral SSRI/SNRI; generic ketamine for psychiatric use is off-label.
• Routes: Spravato is intranasal nasal spray only, in-clinic supervised. Generic ketamine: IV (most studied), IM, sublingual, sometimes compounded intranasal.
• Evidence base: Generic IV racemic ketamine has the larger and longer RCT base; Spravato has the regulatory-approval-standard pivotal trials (Daly 2018, Popova 2019, SUSTAIN-1/2).
• Coverage: Spravato is the form most likely to have private insurance prior-auth coverage in Canada (Canada Life PSHCP Form M7520 for federal public servants; Manulife, Sun Life, Green Shield generally accept prior auth for documented TRD). Generic ketamine for psychiatric use is generally not insurance-covered.
• Operational: Spravato sessions are longer in clinic (≥2-hour mandatory observation post-dose). Generic ketamine sessions are typically 90–120 minutes total.
• Net out-of-pocket for many privately-insured Canadian TRD patients makes Spravato the more affordable pathway despite higher list price.

The molecule — racemic versus S-enantiomer

Pharmaceutical ketamine — the form used in anaesthesia for decades and now off-label for psychiatry — is a racemic mixture: 50% S-enantiomer + 50% R-enantiomer. The two enantiomers are mirror-image molecules with different binding affinities at the NMDA receptor.

• S-enantiomer (esketamine): ~4× greater NMDA receptor affinity than the R-enantiomer.
• R-enantiomer (arketamine): lower NMDA potency but reportedly favourable engagement at other targets.

Spravato isolates only the S-enantiomer as a single-enantiomer drug product. The marketing-and-mechanistic story is that isolating the more potent NMDA antagonist provides a more focused antidepressant effect with potentially fewer side effects from the R-enantiomer.

The clinical translation is more nuanced. Head-to-head comparisons (mostly observational) of IV racemic ketamine versus Spravato in TRD have shown comparable response rates rather than clear S-enantiomer superiority. Some analyses have found IV racemic ketamine non-inferior or modestly superior to Spravato in week-4 response and remission. The honest framing: the molecular advantage of esketamine does not reliably translate into clinical superiority over racemic ketamine in TRD. Patients should not assume "esketamine is better" simply because it is the isolated more-potent enantiomer.

Regulatory status — the headline difference

For the off-label / Schedule I framework explanation, see Is Ketamine Therapy Legal in Canada?. For the Spravato deep dive, see Intranasal Ketamine and Spravato.

Routes and bioavailability

Critical distinction: "Intranasal ketamine" is not a single thing. Spravato (intranasal esketamine) is Health Canada-approved with controlled distribution. Compounded racemic intranasal ketamine is a different product, made at compounding pharmacies, not Health Canada-approved as a manufactured drug, and has been the subject of FDA safety alerts (October 2023) and Health Canada Product InfoWatch caution (March 2022). Patients should ask any clinic that offers "intranasal ketamine" specifically which product is being delivered.

For the modality deep dives, see Intravenous Ketamine Therapy, Intranasal Ketamine and Spravato, and Ketamine Infusion Therapy.

Evidence base — comparing what's been published

Generic IV racemic ketamine RCT base (larger, longer)

• Berman et al. 2000 (Biol Psychiatry) — first IV ketamine RCT in depression. PubMed
• Zarate et al. 2006 (Arch Gen Psychiatry) — pivotal NIMH single-dose IV ketamine RCT in TRD. PubMed
• Murrough et al. 2013 (Am J Psychiatry) — two-site randomized active-controlled trial. PubMed
• Singh et al. 2016 (Am J Psychiatry) — twice-weekly vs thrice-weekly dosing. PubMed
• Phillips et al. 2019 (Am J Psychiatry) — Royal Ottawa Canadian study with maintenance phase. PubMed
• Marcantoni et al. 2020 (J Affect Disord) — meta-analysis of IV ketamine for TRD.
• Anand et al. 2023 ELEKT-D (N Engl J Med) — IV ketamine non-inferior to ECT for nonpsychotic TRD. PubMed
• Swainson et al. 2021 — CANMAT racemic ketamine task force recommendations. PubMed

Spravato pivotal trials (designed for regulatory approval)

• Daly et al. 2018 (JAMA Psychiatry) — Phase 2 dose-response. PubMed
• Popova et al. 2019 TRANSFORM-2 (Am J Psychiatry) — flexibly dosed esketamine + new oral antidepressant. PubMed
• Fedgchin et al. 2019 TRANSFORM-1 (Int J Neuropsychopharmacol) — fixed-dose Phase 3.
• Daly et al. 2019 SUSTAIN-1 (JAMA Psychiatry) — maintenance of efficacy. PubMed
• Wajs et al. 2020 SUSTAIN-2 (J Clin Psychiatry) — long-term safety up to 1 year (n=802). PubMed
• Ochs-Ross et al. 2020 TRANSFORM-3 (Am J Geriatr Psychiatry) — esketamine in elderly TRD.

The honest evidence comparison: both are well-supported in TRD. Generic IV racemic ketamine has a larger and longer RCT base across more diverse populations; Spravato has the regulatory-approval-standard pivotal trial set with extensive long-term safety data on the specific combination protocol (esketamine + oral antidepressant). Direct head-to-head RCTs comparing IV racemic ketamine to Spravato are limited; observational and retrospective real-world comparisons show comparable outcomes.

Coverage asymmetry — the most consequential difference for many patients

This is where the practical decision often gets made.

Spravato — the form most likely to be insurance-covered

In Canada, Spravato has the most established private insurance prior-authorization pathway:

• Canada Life (PSHCP for federal public servants) — Form M7520 prior authorization. Particularly relevant for Ottawa's federal workforce. Reimbursement is typically at 80% of the lowest-priced generic equivalent.
• Manulife, Sun Life, Green Shield, Blue Cross provincial branches — generally accept prior authorization for documented TRD with failed antidepressant trials.
• WSIB Ontario — covers Spravato on Psychotraumatic and Serious Injury formularies for compensable injuries.
• VAC — covers Spravato as non-formulary case-by-case for service-related TRD.
• Public coverage: CDA-AMC Do Not Reimburse recommendation December 2020; INESSS recommended against listing Quebec November 2020; BC PharmaCare non-benefit. Public plans generally do not cover Spravato.

For the typical Canadian patient with documented TRD and private benefits, Spravato with prior authorization is often the most affordable pathway despite a list price of ~$800–$900 per session.

Generic ketamine — generally out-of-pocket

Generic IV/IM/SL ketamine for psychiatric use is generally not covered by private insurance (off-label) and not on provincial drug formularies. Exceptions:

• Edmonton Misericordia/Grey Nuns public IV ketamine program — covered under AHCIP for ultra-resistant TRD with psychiatry referral.
• WSIB Ontario — covers generic ketamine on multiple specialty formularies for compensable injuries.
• WCB Alberta — covers ketamine for compensable CRPS and refractory neuropathic pain.
• VAC — covers generic ketamine drug forms case-by-case for service-related TRD or chronic pain.

The practical reality: for most Canadian patients without WCB/WSIB/VAC eligibility, off-label generic ketamine is private-pay.

For the full Canadian insurance navigation, see Insurance Coverage for Ketamine Therapy.

Cost comparison — list price versus net out-of-pocket

The honest framing: Spravato's higher list price is offset by insurance coverage for many patients. For a fully privately-insured TRD patient, Spravato may be the most affordable pathway by a wide margin. For an uninsured patient, generic IV ketamine at $375/session at the most affordable Canadian clinic (e.g., Ontario Ketamine and Infusion Centre, Mississauga) may be the most affordable pathway. The "right" answer depends on individual coverage and provider availability.

Operational comparison — time, frequency, total course

For patients with inflexible schedules — particularly those on PSHCP / Canada Life pathway with fewer cost barriers — Spravato's longer in-clinic time becomes the trade-off for insurance coverage. For patients prioritizing total course efficiency, generic IV is shorter.

Decision framework — how to think about it

Choose Spravato if:

• You have documented TRD eligible for prior-auth coverage through your private insurance.
• You are a federal public servant with PSHCP coverage (Canada Life Form M7520).
• You have WSIB Ontario or equivalent coverage on Psychotraumatic/Serious Injury formularies.
• The Health-Canada-approved TRD pathway with concurrent oral SSRI/SNRI fits your clinical picture.
• You have access to a Janssen Journey-certified clinic.

Choose generic ketamine (IV / IM / SL) if:

• Your indication extends beyond TRD — PTSD, anxiety, OCD, chronic pain — where Spravato is not approved.
• You prefer the integrated KAP model with bundled preparation, dosing, and integration psychotherapy.
• You're in Edmonton and eligible for the public Misericordia/Grey Nuns AHCIP-covered program.
• You're comparing on the broader IV evidence base (Berman, Zarate, Murrough, Singh, Phillips, ELEKT-D) for your specific severity profile.
• You have WCB or VAC coverage that applies to generic ketamine.

The ATMA CENA intake call screens for both pathways and discusses the realistic access route given your indication, location, coverage, and clinical picture. ATMA CENA's corporate clinics deliver KAT primarily through generic IM and SL ketamine; Spravato-eligible patients are routed via coordinated care where direct administration is not in-house.

Frequently asked questions

Is Spravato better than generic ketamine? Not consistently in head-to-head comparisons. Both work for TRD. The S-enantiomer has greater NMDA receptor affinity, but real-world clinical outcomes are comparable. The decision usually comes down to coverage, route preference, and clinical fit rather than clinical superiority.

Why is Spravato covered by insurance and generic ketamine isn't? Spravato is Health Canada-approved for a specific indication (TRD with concurrent oral SSRI/SNRI). Insurance prior-auth pathways are built around approved indications. Off-label generic ketamine doesn't fit into the standard formulary pathway.

Can I get Spravato in any Canadian province? Yes — Spravato is approved nationally. Janssen Journey-certified providers exist in psychiatric private practice and select hospital affiliates. Confirm local availability (Royal Ottawa BMO Innovative Clinic, Jewish General Montreal, Edmonton hospital affiliates, Numinus locations are among confirmed sites).

Does generic ketamine have a stronger evidence base? For TRD specifically, IV racemic ketamine has a larger and longer RCT base (the chain from Berman 2000 through Anand 2023 ELEKT-D). Spravato has the regulatory-approval-standard pivotal trials with extensive long-term safety data on a specific combination protocol. Both are well-supported.

What if I can't access a Janssen Journey-certified clinic? Generic IV/IM/SL ketamine is the alternative. The ATMA CENA intake call can discuss which ATMA CENA corporate clinic, member clinic, or coordinated care arrangement fits your geography.

Is the Spravato observation period really 2 hours? Yes — it's a Health Canada requirement under the Janssen Journey program. Patients are monitored for sedation, dissociation, and blood pressure changes during the observation period. Plan ~2.5–3 hours total in clinic per session, plus a designated driver.

Can I do Spravato without an oral antidepressant? Spravato's Health Canada-approved indication is specifically TRD with concurrent oral SSRI/SNRI. Off-label use of Spravato as monotherapy would be at the prescribing physician's discretion outside the approved indication.

Does Spravato have fewer side effects than generic ketamine? The acute side-effect profile is broadly similar — dissociation, transient BP elevation, mild nausea, sedation. SUSTAIN-2 (Wajs 2020) demonstrated acceptable long-term safety for Spravato + oral antidepressant up to 1 year. Murrough 2015 demonstrated short-term safety of repeated IV ketamine. Both are well-tolerated at therapeutic supervised doses. See Ketamine Therapy Side Effects.

What about compounded intranasal ketamine? Compounded racemic intranasal ketamine is not Spravato and is not Health Canada-approved as a manufactured drug. FDA safety alerts (October 2023) and Health Canada Product InfoWatch (March 2022) describe risks of unsupervised compounded use. If a clinic offers "intranasal ketamine," confirm specifically whether it is Spravato or a compounded preparation.

Does ATMA CENA offer both? ATMA CENA's corporate clinics deliver KAT primarily through generic IM and SL ketamine. ATMA CENA's specific Janssen Journey certification status should be confirmed at intake; Spravato-eligible patients can be routed via coordinated care to certified providers where appropriate.

Where can I learn more about each? See Intranasal Ketamine and Spravato for the Spravato deep dive, Intravenous Ketamine Therapy for the IV deep dive, and Ketamine Infusion Therapy for the patient-friendly umbrella overview.

Sources

1. ATMA CENA — coordinated care: https://psychedelic.healthcare/find-care
2. Health Canada DPD — Spravato: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
3. Daly EJ, et al. (2018). Phase 2 dose-response esketamine in TRD. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/29282469/
4. Popova V, et al. (2019). TRANSFORM-2 — esketamine + new oral antidepressant in TRD. Am J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/31109201/
5. Daly EJ, et al. (2019). SUSTAIN-1 — Spravato maintenance of efficacy. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/31268507/
6. Wajs E, et al. (2020). SUSTAIN-2 — Spravato long-term safety. J Clin Psychiatry. https://pubmed.ncbi.nlm.nih.gov/32316080/
7. Zarate CA Jr, et al. (2006). Randomized trial of an N-methyl-D-aspartate antagonist in TRD. Arch Gen Psychiatry. https://pubmed.ncbi.nlm.nih.gov/16894061/
8. Murrough JW, et al. (2013). Antidepressant efficacy of ketamine in TRD: two-site RCT. Am J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/23982301/
9. Anand A, et al. (2023). Ketamine versus ECT for nonpsychotic TRD: ELEKT-D. N Engl J Med. https://pubmed.ncbi.nlm.nih.gov/37224135/
10. Swainson J, et al. (2021). CANMAT racemic ketamine task force recommendations. Can J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/33174760/
11. Canada Life — Spravato Prior Authorization Form M7520 (PSHCP): https://www.welcome.canadalife.com/content/dam/canadalife/documents/forms/you-and-your-family/1-0-employer/1-3-request-an-assessment/1-3-2-prior-auth-drugs/en/pshcp/spravato-m7520.pdf
12. CDA-AMC — Spravato CDEC Final Recommendation (December 2020): https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0621%20Spravato%20-%20CDEC%20Final%20Recommendation%20December%2018,%202020_for%20posting.pdf
13. FDA — Compounded ketamine safety alerts (October 2023): https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine

Related articles in this cluster

• Ketamine Therapy in Canada
• What Is Ketamine Therapy?
• Intravenous Ketamine Therapy
• Intranasal Ketamine and Spravato
• Ketamine Infusion Therapy
• Ketamine Therapy for Treatment-Resistant Depression (deep dive)
• Ketamine vs Antidepressants
• Ketamine vs Psilocybin Therapy
• How Many Ketamine Treatments Do I Need?
• Insurance Coverage for Ketamine Therapy
• Ketamine Therapy Side Effects
• Find care near you

Last updated: 2026-05-06